Jin, Lei

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature

Sirtuins and Resveratrol in MedicineNatural Antidiabetic Agents Studies

Cited by 1,707

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology

Epigenetics and DNA MethylationCancer-related gene regulation

Cited by 776

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood

Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia research

Cited by 722

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology

Cancer-related gene regulationProtein Degradation and Inhibitors

Cited by 569

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery

Acute Myeloid Leukemia ResearchGlioma Diagnosis and Treatment

Cited by 471